The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

NCT06674694 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia Disorders

Interventions

DRUG: Brexpiprazole long-acting injection

Sponsor

Sichuan Kelun Pharmaceutical Co., Ltd